Colombo M P, Forni G
Gene Therapy Program and Experimental Oncology D, Istituto Nazionale Tumori, Milan, Italy.
Cancer Metastasis Rev. 1997 Sep-Dec;16(3-4):421-32. doi: 10.1023/a:1005980418533.
The cytokine approach to gene therapy of cancer stems from early studies of direct, repeated injection of recombinant cytokines at the tumor site, and extension of the bystander effect that enables a few cytokine gene transduced cells in a tumor to bring about its total destruction. This effect can be extended through the immune system, since cytokine-activated regression of a small mass of tumor cells can afford systemic protection. Transduced cells used as a vaccine provide a local concentration of both cytokine and tumor antigens. Cytokines sustain antigen uptake and presentation by increasing the immunogenic potential of the environment through the recruitment of antigen presenting cells and leukocytes, and activation of a cascade of events which amplify and tone up the efficacy of a vaccine. The promises and difficulties of this approach are discussed by considering what is still missing from experimental studies and what can best be done as soon as possible in animals and humans to reach compelling conclusions.
癌症基因治疗的细胞因子方法源于早期在肿瘤部位直接、重复注射重组细胞因子的研究,以及旁观者效应的扩展,即肿瘤中少数转导细胞因子基因的细胞能够导致肿瘤完全破坏。这种效应可以通过免疫系统扩展,因为少量肿瘤细胞经细胞因子激活后的消退可提供全身保护。用作疫苗的转导细胞可在局部提供细胞因子和肿瘤抗原。细胞因子通过招募抗原呈递细胞和白细胞,增加环境的免疫原性潜力,并激活一系列放大和增强疫苗效力的事件,从而维持抗原摄取和呈递。通过考虑实验研究中仍缺失的内容以及在动物和人类中尽快采取何种最佳措施以得出令人信服的结论,来讨论这种方法的前景和困难。